X

Aggrego On Site

Top Stories
More NSCLC Downstaging With Neoadjuvant Chemotherapy Plus ICI

Neoadjuvant chemotherapy plus nivolumab resulted in a higher frequency of disease downstaging and lower frequency of upstaging compared with other therapies among patients with...

Cancer Therapy Advisor
11/12/2020
OncoMyx’s Oncolytic Virus Platform Shows Preclinical Efficacy, Boosting Immunotherapy Potential

Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted onco

11/17/2020
``

ASH 2021: Updates in AML

Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that four abstracts have been accepted for presentation – including three oral presentations and one poster presentation – at the 63rd American Society of Hematology (ASH) Annual Meeting taking place Dec. 11-14, 2021.

11/04/2021
Routine Screening for Germline Variants in Patients With AML

Nearly 14% of adult patients with acute myeloid leukemia have pathogenic or likely pathogenic germline variants that make them susceptible to myeloid malignancies.

ASH Clinical News
11/01/2021
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced positive top-line results from an investigator-initiated Phase 2 clinical trial of MGTA-145 stem cell mobilization in multiple myeloma.

11/04/2021
MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that three abstracts highlighting data and information from three oncology drug candidates in its pipeline will be presented at the upcoming 63rd Annual American Society of Hematology (ASH) Annual Meeting to be held December 11 – 14, 2021.

11/04/2021

ASH 2021: Updates in BCMA + CAR-T

FDA Delays Decision on Ciltacabtagene Autoleucel CAR-T for Advanced Multiple Myeloma

The FDA delayed its decision on a biologics license application for ciltacabtagene autoleucel, a CAR T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.

Healio
11/02/2021
FDA Expects Decision on Cilta-cel Approval by February 2022

The FDA is expected to decide by the end of February whether or not to approve ciltacabtagene autoleucel, an investigational CAR T-cell therapy for the treatment of R/R multiple myeloma.

11/03/2021
CD38 CAR-T Cell Therapy May Be Promising for Patients With Multiple Myeloma

A novel CAR T-cell therapy targeting CD38 may be an effective option for multiple myeloma, according to research published in Frontiers in Oncology.

Hematology Advisor
11/04/2021
FDA Grants RMAT Designation to CRISPR-Edited CAR-T for Advanced B-Cell Malignancies

The FDA granted regenerative medicine advanced therapy designation to CTX110, a CAR T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

Healio
11/29/2021
CAR-T ‘Clearly Superior’ For Triple-Class Refractory Multiple Myeloma

CAR T-cell therapy has induced exceptional response rates among patients with R/R multiple myeloma compared with conventional options, according to a speaker at Chemotherapy Foundation Symposium.

Healio
11/12/2021
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021

RARITAN, N.J., Nov. 4, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.

11/04/2021

ASH 2021: Updates in CLL

AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present new data underscoring its commitment to transforming hematologic cancer care at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11 to 14, 2021.

11/05/2021
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

LONDON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced an oral presentation related to the industrialization of its manufacturing process and poster presentations related to its obe-cel (AUTO1) and AUTO1/22 programs, the company’s CAR T cell product candidates being investigated in adult ALL (the FELIX study) and Pediatric ALL (the CARPALL study), respectively, at the 63rd ASH Annual Meeting & Exposition, being held between December 11-14, 2021. 

11/04/2021
InnoCare to Present Orelabrutinib Data at the Upcoming 63rd Annual Meeting of ASH

BEIJING, Nov. 9, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company will present latest data of its BTK inhibitor orelabrutinib at the 63rd American Society of Hematology (ASH) Annual Meeting on December 11-14, 2021, which will be hold online and offline in Atlanta, Georgia.

11/09/2021
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced clinical results and real world data from its hematology program to be presented at the 63rd ASH Annual Meeting and Exposition, including two oral presentations on the Phase 3 SEQUOIA trial comparing BRUKINSA® (zanubrutinib) to bendamustine and rituximab (B+R) in patients with treatment-naïve CLL or SLL. The ASH meeting will take place on December 11-14, 2021, as a hybrid event in Atlanta, GA and in a virtual format.

11/04/2021

ASH 2021: Updates in DLBCL TV

Limitations of CAR T-cell Therapy for DLBCL

Dr Adrienne Phillips shares her thoughts on immunotherapies for relapsed diffuse large B-cell lymphoma.

12/01/2021
How Does Biomarker Testing Impact DLBCL Treatment Options?

Dr Loretta Nastoupil explains how biomarkers are currently used in determining an optimal treatment approach and how research efforts could help create more precise treatments.

10/20/2021
John Leonard, MD, Discusses the Lymphoma Treatment Landscape

Dr John P. Leonard discusses the complex landscape and management of patients with lymphoma, as well as hot topics in hematologic malignancies, including the use of monsunetuzumab therapy.

Oncology Learning Network
12/04/2021

ASH 2021: Updates in MCL

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

SUZHOU, China, and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on six studies of the company's three drug candidates (olverembatinib [HQP1351], lisaftoclax [APG-2575], and pelcitoclax [APG-1252]) have been selected for poster presentations and one oral presentation at the 63rd ASH Annual Meeting. These data include two clinical studies of the company's novel Bcl-2-selective inhibitor lisaftoclax and one preclinical study of the dual Bcl-2/Bcl-xL inhibitor pelcitoclax.

12/04/2021

SABCS 2021: Updates in HER2+

Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS

MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) will present new breast cancer research data across its DXd ADC portfolio at the 2021 San Antonio Breast Cancer Symposium (#SABCS21) to be held December 7 to 10, 2021.

12/01/2021
Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December

WESTPORT, Conn., Nov. 30, 2021 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that new breast cancer data from its phase 1/2 study IT-01 using novel lead asset, INT230-6, will be presented at the SABCS being held virtually and in-person at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 7-10, 2021.

11/30/2021
Large-Scale Genomic Sequencing Reveals Adaptive Opportunity of Targeting Mutated-PI3Kα in Early and Advanced HER2+ Breast Cancer

Study authors characterized the adaptive roles of PI3Kα mutations among HER2+ tumor progression.

Clinical and Translational Medicine
12/04/2021

SABCS 2021: Updates in HER2 Low

CDK4/6 Inhibitors Combined With Fulvestrant for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: FDA Analysis of Overall Survival

Dr Jennifer Gao and colleagues found the addition of CDK4/6 inhibitor treatment to fulvestrant resulted in a consistent OS benefit vs placebo plus fulvestrant in patients with HR+.

The ASCO Post
12/09/2021
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that two abstracts and posters have been accepted for presentation at the upcoming SABCS.

11/11/2021
Spotlight

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834